The most commonly prescribed class of immunotherapies (called ICIs, immune checkpoint inhibitors) are not free from fulminant and fatal toxic side effects; the researchers of the Vanderbilt-Ingram Cancer Center recently evaluated their toxicities, publishing the [more]
A spate of recent studies suggest that differences in population of bacteria and other micro-organisms that inhabit our intestines may be a key factor differentiating between people who respond to immune checkpoint inhibitors and those [more]
A chromosomal alteration present in almost all patients with Hodgkin lymphoma makes the disease uniquely vulnerable to PD-1/PD-L1 immune checkpoint blockers. Astrid Pavlovsky reviews the trial evidence and clinical experience, and looks to the future [more]
When we talk about advances in cancer care patient advocacy groups tend to focus on the development of new drugs, immunotherapy being the latest flavour. This is encouraged by the pharma industry, keen to gain [more]
Engaging the body’s own immune system in controlling cancer has long been an aspiration for cancer researchers and clinicians. This overview looks at progress towards that goal, and how it is changing the paradigm of [more]
The concept is attractive, the results in some patients have been stunning, but what will it take to extend these impressive responses to wider groups of patients? Peter McIntyre reports. There is a growing sense [more]
Building a lung cancer team that works seamlessly to do the best for each patient was the biggest challenge in Enriqueta Felips career. Her focus today is on increasing collaboration across Europe, which she sees [more]
Understanding what drives cancer cells to break loose, travel around the body and seed new tumours and how to inhibit this process will be key to developing effective new therapies Metastasis – the [more]
With our new-found understanding of cancer biology comes the opportunity to explain a disease that for centuries has confounded doctors and engendered stigma and superstition. Siddhartha Mukherjee took that opportunity and turned it into a [more]
With two novel immunotherapies approved and many more in the pipeline, is it time to announce that a new treatment modality has emerged? A class of therapy that has long held promise for treating cancer [more]
Selected reports edited by Hannah Brown Download full article